source
- FDA pushes back decision on Exelixis' zanzalintinib and Roche's Tecentriq combo for metastatic colorectal cancerThe FDA announced a delay in its decision on the approval of Exelixis' oral kinase inhibitor zanzalintinib when used with Roche's Tecentriq for metastatic colorectal cancer. The agency said it nee…
- Owkin and Servier partner to use AI platform K Pro for oncology discovery and trial designOwkin, an AI drug-discovery CRO, has entered a new agreement with French pharmaceutical company Servier to license its AI scientist, K Pro, for use in Servier’s oncology research and clinical trial…Fierce Biotech · 2mo agoDealPositive